Strides receives approval for Efavirenz

Strides receives approval for Efavirenz

Our News BureauMumbai

2007043012-5748096Strides Arcolab has received tentative approval from the USFDA for Efavirenz tablets under the expedited review provisions of the President’s Emergency Plan for Aids Relief (PEPFAR) programme. Efavirenz, the generic version of Bristol Myers Squibb’s Sustiva, is a non-nucleoside reverse transcriptase inhibitor which prevents the AIDS virus from reproducing in cells. Efavirenz is used in combination with other anti-retroviral agents for the treatment of HIV-infections and is a key component of drug regimens for patients who are on concurrent treatment for tuberculosis.

Speaking on the occasion, Arun Kumar, Vice-Chairman and Managing Director, Strides Arcolab said, “We now have ANDA/NDA approvals for all first line anti-retroviral drugs. This will give a major boost to our AIDS, TB and malaria (ATM) initiative particularly in Africa and South Asian countries.”